Urine sodium concentration and diuretic responsiveness in dogs receiving orally administered loop diuretics for chronic congestive heart failure Authors: Audrey Rollins, Darcy B Adin, Alexandra V Crooks, Samantha Siess, Yeonji Cho, Ana Mijares, Ingrid Ljungvall, Mark A Oyama Published: 2026 ABSTRACT AbstractBackgroundUrine sodium concentration (uNa) measures diuretic responsiveness (DR) in acute congestive heart failure (CHF). In humans with chronic CHF receiving loop diuretics PO, low uNa is associated with rehospitalization and mortality. DR in dogs with chronic CHF is poorly understood.Hypothesis/ObjectivesMeasure uNa and pharmacologic and pathophysiologic variables in dogs receiving loop diuretics PO for chronic CHF.AnimalsEleven client-owned dogs.MethodsProspective longitudinal observational study. Owners collected multiple convenience urine samples over 5 days. Associations between urine electrolyte, creatinine, and loop diuretic concentrations, dose and duration of PO diuretic treatment, and time from previous diuretic administration or feeding were examined using mixed effects linear regression.ResultsA total of 189 samples were collected. Median uNa was 27 mmol/L (IQR, 10-61 mmol/L). Dose and time from previous PO diuretic or feeding were not significantly associated with uNa. In 5 of 11 (45%) dogs, uNa < 70 mmol/L was observed consistently and indicative of low DR. Urine diuretic concentration was not significantly associated with uNa (β, 0.29; 95% CI, −0.03 to 0.61; P = .08) or diuretic dose, duration of treatment, or time from last PO diuretic or feeding. Individual variability was high. Observed patterns of uNa, diuretic dose, and urine diuretic concentration suggested potential causes of low DR.Conclusions and clinical importanceMeasurement of uNa and diuretic concentration identifies dogs with low natriuresis, which is not predicted by diuretic dose or duration. Observation of uNa patterns generates hypotheses regarding potential causes of low DR that warrant confirmation in larger studies. Introduction Orally administered loop diuretics, such as furosemide and torsemide, are prescribed routinely to dogs with chronic congestive heart failure (CHF).1 The efficacy of orally administered loop diuretics is determined by multiple different pharmacologic and physiologic factors, including gastrointestinal bioavailability, renal blood flow, secretion of drug across proximal tubular epithelial cells into the nephron lumen, and binding of drug to the intraluminal Na-2Cl-K cotransporter in the ascending loop of Henle. Efficacy also means that the resulting increase in luminal sodium concentration and net natriuresis and diuresis are not counteracted in more distal nephron segments. Diuretic responsiveness (DR) generally has been defined as the clinicopathological effects of urinary sodium and water loss and subsequent relief or prevention of clinical signs secondary to congestion.2,3 Low DR, also referred to as diuretic resistance, is defined as a quantity of water or sodium less than what typically is expected after appropriate diuretic usage.4,5 Measurement of spot urine sodium concentration (uNa) is one of several quantitative measures of DR.3,6,7 For example, spot uNa <50-70 mmol/L after loop diuretic administration is a criterion for low DR in humans with acute CHF.3 This and other quantitative measures of DR guide treatment and predict important clinical outcomes in humans.3,8,9 In humans and dogs, spot uNa is correlated with total natriuresis, which is the product of uNa and urine volume resulting diuretics administered IV or PO.10,11 Dogs with low spot uNa possess other clinicopathological characteristics consistent with low DR, including weight gain, longer hospitalization times, and low total natriuresis.10 The daily patterns of uNa in dogs receiving loop diuretics PO for chronic CHF are unknown. Our aim was to examine the association between uNa and dose and duration of orally administered loop diuretics, timing of drug administration and feeding, and urine diuretic concentration. Our goals were to characterize patterns of uNa, identify whether low DR occurs in dogs with chronic CHF, and generate hypotheses for underlying mechanisms. Materials and methods A prospective multisite study was designed. Approval was obtained from the Institutional Animal Care and Use Committees at each site. Dogs without clinical signs of congestion and receiving stable doses of furosemide or torsemide PO for chronic left or right sided CHF for ≥7 days were eligible for inclusion. Other inclusion criteria included an echocardiogram having been performed within the previous 90 days. Dogs with clinically important comorbidities, such as those that might affect kidney function, were excluded based on the judgment of the attending investigator. Owners were supplied with plain red top tubes to collect as many voided urine samples over 5 days as convenient. Owners recorded time of urine collection, medication administration, and feeding in a provided diary. Times between collection, the most recent meal, and diuretic administration were calculated for each urine sample. Dietary sodium was calculated using manufacturer supplied sodium and caloric content and the owner’s feeding diary. The amount of ingested sodium at each meal (mg) was indexed to body weight (mg/kg). Urine samples were stored in the owner’s refrigerator before mailing to the investigators on day 6. Measurements of uNa, urine chloride concentration (uCl), urine potassium concentration (uK), and urine creatinine concentration (uCr) were performed by the clinical pathology laboratory at University of Pennsylvania. Urine sodium concentration was divided by uK to determine a ratio (uNa:K). Aliquots of urine were frozen at −80 °C until batch analysis of urine loop diuretic concentration at North Carolina State University using high performance liquid chromatography as previously described.12 Data were analyzed for normality using D’Agostino-Pearson tests. Non-normal data were log transformed. Data were tabulated and presented as either median and IQR, mean ± SD, or count and percentage. Oral torsemide doses and urine concentrations of torsemide were converted to furosemide equivalents (uFureq) using a ratio of 1:10.1,13 Based on criteria used in humans and proposed in dogs,3,5,10 dogs with observed uNa consistently <70 mmol/L were considered as having low DR. Correlations between dog-related variables were assessed by calculation of the Spearman correlation coefficient (ρ). Associations between urine electrolytes, uFureq, dose, dietary sodium intake, and time from PO diuretics or feeding were examined in a stepwise manner to better identify and understand the effect of individual variability, beginning with crude estimates from simple linear regression followed by mixed effects linear regression.14 The mixed models accounted for the repeated nature of the data by including dog as a grouping variable and permitted closer examination of the random effects associated with between-dog variance (ie, random y-intercept) and within-dog variance (ie, random slope). Nested mixed models adding day and order of sample collection as additional grouping variables also were explored. Examination of residuals, Akaike’s information criterion (AIC), and likelihood ratio tests were used to assess goodness of model fit, compare crude and adjusted models, and explore different covalence structures with unstructured being the default. Smaller AIC values indicated better fit and a significant likelihood ratio test between parent and nested models indicated that one model had significantly better fit than the other. We performed sensitivity testing of the main analyses using alternative torsemide to furosemide equivalence conversion ratios of 1:8, 1:12, and 1:16.15 Statistical and graphing software (STATA BE18, StataCorp, College Station, TX USA; Prism 9, GraphPad Software, San Diego, CA USA) were used to perform analyses. Results Eleven dogs were recruited including 7 from University of Pennsylvania and 4 from University of Florida. Signalment, medication history, and echocardiographic findings are shown in Table 1. Nine of 11 (82%) dogs were receiving furosemide PO and 2 of 11 (8%) dogs were receiving torsemide PO. Heart diseases in the study cohort included myxomatous mitral valve disease in 4 of 11 (36%) dogs, idiopathic dilated cardiomyopathy in 4 of 11 (36%) dogs, and pulmonic stenosis in 3 of 11 (27%) dogs. Breeds included 2 of 11 (18%) English bulldogs, 2 of 11 (18%) mixed breed dogs, and 1 of 11 (9%) dogs of the following breeds: Shih Tzu, Doberman pinscher, American bulldog, French bulldog, Havenese, Boxer, and Basenji. One dog was being fed a variable homemade diet. Dietary sodium content was calculated for the remaining 10 dogs (Table 1). One hundred and eighty-nine uNa measurements were made over the study period with a median of 18 samples (IQR, 11-24 samples) from each dog. The median time from the most recent PO loop diuretic to urine sample collection was 6.2 h (IQR, 2.1-10.8 h) and the median time from most recent feeding to urine sample collection was 5.2 h (IQR, 2.2-10.8 h). Neither age (ρ, −0.12; 95% CI, −0.68 to 0.53; n = 11; P = .73) nor weight (ρ, 0.25; 95% CI, −0.43 to 0.75; n = 11; P = .47) were significantly correlated with the dogs’ median uNa. Urine electrolyte and creatinine concentrations are shown in Table 2. Median uNa was not significantly correlated with duration of treatment (ρ, 0.43; 95% CI, −0.25 to 0.82; n = 11; P = .19), daily PO diuretic dosage (ρ, −0.15; 95% CI, −0.70 to 0.51; n = 11; P = .65), or daily dietary sodium intake (ρ, −0.30; 95% CI, −0.78 to 0.41; n = 10; P = .41). Urine electrolyte, creatinine and diuretic concentrations, and time from previous PO diuretic and feeding were not normally distributed and were log transformed for all regression analyses. uNa was not significantly associated with the most recent PO furosemide or furosemide equivalent dose (β, 0.03; 95% CI, −0.39 to 0.46; n = 177; P = .88) or with the amount of sodium ingested in the most recent meal (β, −0.001; 95% CI, −0.010 to 0.005; n = 151; P = .80). uNa was not significantly correlated with time from previous PO loop diuretic (β, 0.04; 95% CI, −0.06 to 0.14; n = 178; P = .47) or time from previous feeding (β, −0.01; 95% CI, −0.14 to 0.11; n = 165; P = .83; Figure 1). In 5 of 11 (45%) dogs, uNa was <70 mmol/L in all collected samples (n = 100), suggesting low DR. Table 1Signalment, daily dietary sodium intake, medication history, and echocardiographic measurements of 11 dogs receiving PO loop diuretics. N Central tendency Age (years) 119.6 (8.5-11.5) Weight (kg) 1116.7 ± 12.3 Sex 113 Male, 8 female Daily sodium intake (mg/kg body weight) 1052 (29-116) Oral furosemide equivalents (mg/kg/day) 113.4 ± 0.96 Spironolactone (mg/kg/day) 92.1 ± 0.5 Angiotensin converting enzyme inhibitor (mg/kg/day) 70.80 ± 0.26 Pimobendan (mg/kg/day) 110.66 (0.56-0.78) Normalized left ventricular end diastolic dimension 111.7 ± 0.6 Normalized left ventricular end systolic dimension 110.94 ± 0.43 Normalized left interventricular septum wall thickness 110.45 ± 0.06 Normalized left ventricular posterior wall thickness 110.54 ± 0.13 Fractional shortening (%) 1143 ± 5 Left atrium to aortic root diameter ratio 112.0 ± 0.6 Duration of PO loop diuretic treatment (months) 118.1 ± 10Data are shown as mean ± SD, median (interquartile range), or count. Signalment, daily dietary sodium intake, medication history, and echocardiographic measurements of 11 dogs receiving PO loop diuretics. Data are shown as mean ± SD, median (interquartile range), or count. Table 2Urine electrolyte and creatinine concentrations in urine samples collected by dog owners in 11 dogs during the 5-day study. N Central tendency Sodium (mmol/L) 18927 (10-61) Potassium (mmol/L) 19437 (22-73) Chloride (mmol/L) 19334 (14-18) Creatinine (mg/dL) 19443 (25-86) Sodium:Potassium ratio 1890.72 (0.34-1.4)Data are shown as median (interquartile range). Urine electrolyte and creatinine concentrations in urine samples collected by dog owners in 11 dogs during the 5-day study. Data are shown as median (interquartile range). Relationship of urine sodium concentration (uNa) and (A) hours since last PO diuretic dose and (B) hours since last feeding in 11 dogs receiving PO loop diuretics. Urine furosemide equivalent concentrations were determined in 175 samples from 10 dogs. Median uFureq was 7.0 μg/mL (IQR, 3.9-11.3 μg/mL). Median uFureq was not significantly correlated with duration of treatment (ρ, 0.32; 95% CI, −0.36 to 0.78; n = 10; P = .34) or daily PO diuretic dose (ρ, −0.02; 95% CI, −0.71 to 0.53; n = 10; P = .97). Urine furosemide equivalent concentrations were not significantly associated with the most recent administered PO diuretic dose (β, 0.16; 95% CI, −0.20 to 0.52; n = 164; P = .37) or with time from most recent dose to urine collection (β, 0.04; 95% CI, −0.07 to 0.14; n = 178; P = .47). Urine sodium concentration, uCl, uK, uCr, and uNa:K were significantly associated with uFureq when using simple regression, but only uNa:K remained significant in the mixed effects linear models (Table 3, Figure 2). The mixed effects models demonstrated better goodness-of-fit compared with unadjusted simple models, indicating an important effect of dog identity on the relationship between urine electrolytes and uFureq. Mixed models with additional grouping variables, such as day and collection sequence, did not substantially change estimates or improve model fit (data not shown). Sensitivity testing performed over a range of furosemide to torsemide equivalency constants from 1:8 to 1:16 did not affect results (data not shown). Table 3Association between log transformed urine electrolyte and creatinine concentrations and log transformed urine furosemide equivalent concentration in 10 dogs receiving PO loop diuretics. Coefficient/estimate SE 95% CI AIC P uNa (n = 171) a Unadjusted0.480.080.33-0.63488<.001 b Multilevel mixed effects0.290.17−0.03 to 0.61440.075 Between dog variance1.671.150.43-6.45Within dog variance0.160.130.03-0.75Residual variance0.580.670.46-0.73 uCl (n = 174) a Unadjusted0.330.060.20-0.46431<.001 b Multilevel mixed effects0.080.16−0.23 to 0.39345.62 Between dog variance1.760.960.60-5.12Within dog variance0.190.110.06-0.59Residual variance0.310.030.24-0.38 uK (n = 175) a Unadjusted0.330.060.21-0.46432<.001 b Multilevel mixed effects−0.010.05−0.11 to 0.10223.87 Between dog variance0.830.430.31-2.27Within dog variance0.010.020.00-0.72Residual variance0.150.020.12-0.19 uNaK (n = 171) a Unadjusted0.160.080.02-0.31474.030 b Multilevel mixed effects0.330.090.16-0.50459<.001 Between dog variance0.150.120.03-0.73Within dog variance0.000.010.00-0.53Residual variance0.720.080.58-0.90The unadjusted simple linear regression model does not account for the repeated measure structure of the data and is presented for comparison to the mixed effects model, which takes repeated measures into account at the level of the dog. The mixed model provides estimates of the relative effect of between- and within-dog differences on the relationship between urine electrolyte and furosemide equivalent concentrations. The residual variance is a measure of the variability in the model due to a variable or variables that were unmeasured or unaccounted for in the study. Goodness of model fit is measured by Akaike information criteria (AIC) score where lower numbers mean better model fit. Association between log transformed urine electrolyte and creatinine concentrations and log transformed urine furosemide equivalent concentration in 10 dogs receiving PO loop diuretics. The unadjusted simple linear regression model does not account for the repeated measure structure of the data and is presented for comparison to the mixed effects model, which takes repeated measures into account at the level of the dog. The mixed model provides estimates of the relative effect of between- and within-dog differences on the relationship between urine electrolyte and furosemide equivalent concentrations. The residual variance is a measure of the variability in the model due to a variable or variables that were unmeasured or unaccounted for in the study. Goodness of model fit is measured by Akaike information criteria (AIC) score where lower numbers mean better model fit. Relationship of urine sodium concentration (uNa) and urine furosemide equivalent concentration (uFureq) in 10 dogs receiving PO loop diuretics. The high degree of between and within dog variability prompted us to explore individual patterns of uNa and uFureq to generate additional hypotheses (Figure 3). We observed dogs with low uNa and low uFureq, which suggests poor gastrointestinal availability, poor renal blood flow, or impaired tubular secretion. We observed dogs with low uNa and high uFureq, which suggests impaired intrinsic nephron responsiveness, such as impaired tubuloglomerular feedback, neurohormonal activation, or hypertrophy of the distal convoluted tubule. Finally, we observed dogs with relatively high uNa and uFureq that appear to be at the ceiling of the diuretic dose response curve. Relationship of urine furosemide equivalent concentration (uFureq) indexed to daily PO furosemide equivalent dose (mg/day) and urine sodium concentration (uNa) in 10 dogs receiving PO loop diuretics for chronic right or left-sided CHF. Individual dogs are identified by number. Three dogs with right heart failure are denoted by an italicized number. Two dogs receiving PO torsemide are denoted by an underlined number. A high degree of individual variability is present affecting both the y-intercept and slope of the relationship. Dogs with patterns of low uNa (orange dotted lines) are suspected to have poor diuretic responsiveness compared dogs with higher uNa (purple solid lines). Low uNa and low uFureq to dose ratio might be explained by poor gastrointestinal availability, poor renal blood flow, or impaired tubular secretion. Low uNa and high uFureq to dose ratio might be due to impaired intrinsic nephron responsiveness, such as impaired tubuloglomerular feedback, neurohormonal activation, or hypertrophy of the distal convoluted tubule. Dogs with high uNa and high uFurEq to dose ratio appear to be at the ceiling of the dose–response effect. Discussion An important finding of our study was the heterogeneity of uNa in dogs receiving loop diuretics PO. In our study, we used spot uNa measurements performed over multiple consecutive days to characterize overall natriuretic response and sodium avidity. These observations were considered in relation to important clinicopathological variables such as dose, timing of dose, and feeding. In humans and dogs with CHF, spot uNa is correlated with total natriuresis over a range of different durations of time, from several hours to days.3,10,16 An important finding of our study was the considerable proportion of dogs with consistently low uNa and suspected low DR. The observed uNa concentrations in our cohort with CHF were considerably lower than in healthy dogs12,17,18 and comparable to other studies of dogs with CHF.19 In one of the study of healthy dogs,18 2 mg/kg PO furosemide was associated with uNa between 110 and 147 mmol/L in the first 3 h, followed by 67-110 mmol/L in the subsequent 3 h. Results were similar when receiving the same dose IV. In contrast, in a study19 of dogs with myxomatous mitral valve disease receiving furosemide PO, median uNa in samples obtained between 0-6 h and 6-12 hours of dosing were 71 and 36 mmol/L, respectively. One potential explanation for low uNa in CHF is neurohormonal activation and increased sodium avidity, which are hallmarks of the CHF phenotype regardless of the underlying cause. Another important finding of our study was that uNa was not associated with timing of diuretic administration or feeding, diuretic dosage, or duration of PO diuretic administration. The considerable absence of association between uNa and time from previous diuretic dose was unexpected. In a previous cross-sectional study of dogs with CHF,19 uNa and fractional excretion of sodium were highest in dogs evaluated within 6 h of PO furosemide compared with a separate cohort evaluated 12 h after dosing. The study concluded that urine collection >6 h from PO diuretics was not informative, but the 2 studies differed in potentially important ways. In our study, serial observations of uNa indicated complex patterns in individuals that would be difficult to appreciate in cross-sectional studies. Our study suggested the presence of underlying mechanisms that would delay or impair response beyond the initial dosing period and a high degree of variability in individual responsiveness, which limits the generalizability of cross-sectional study results. In humans, spot uNa from first morning samples, which are collected as many as 12 h from previous PO diuretic administration, are associated with important clinical outcomes.16,20,21 In our study, the observed disconnect between anticipated natriuretic response and dose and timing of treatment is consistent with the definition of low DR.22 Use of uNa to detect low DR has been described in dogs. In 1 prospective study, dogs with chronic CHF received 3 mg/kg furosemide PO, and total natriuresis over the subsequent 7 h was lower in dogs with spot uNa <60 mmol/L compared with dogs with higher concentrations.10 In a second retrospective study involving dogs hospitalized for acute CHF treated at a mean dosage of 3 mg/kg furosemide IV, spot uNa <87 mmol/L was associated with low DR and longer duration of supplemental oxygen dependency.23 In our study, substantial between and within-dog variability and an absence of significant association between uNa and uFureq were observed. The mixed model analyses indicated the strong effect of dog-related variability and demonstrated better goodness-of-fit than unadjusted simple models despite the weaker association with uNa.14 We observed variability in the association between uNa and uFureq related to baseline uNa concentration among dogs (ie, differences in y-intercept) and responsiveness of uNa to uFureq concentration (ie, slope of the uNa to uFureq relationship) within dogs. Observation of these patterns shed light on potential pathophysiologic and pharmacologic reasons for low DR, including low bioavailability, impaired tubular secretion, intrinsic nephron responsiveness, or neurohormonal activation. In our study, a subset of dogs with low DR was observed to also have relatively low uFureq compared with other dogs receiving similar diuretic doses PO. This finding suggests specific pharmacokinetic or pathophysiologic mechanisms of low DR, such as low gastrointestinal bioavailability, tubular secretion, or renal blood flow. These impairments decrease the efficiency with which PO diuretics appear in the urine, and the low uFureq would decrease subsequent natriuresis. Gastrointestinal bioavailability of furosemide as well as rate of absorption of torsemide are decreased when these drugs are administered with food,24,25 but our observations of uFureq and timing of feeding were not consistent with this effect, which might have been masked by other variables. Gastrointestinal function can be compromised by right heart failure (HF), but we were unable to investigate this effect because of the small number of dogs. Once absorbed in the gastrointestinal tract, furosemide and torsemide are secreted from the blood across the proximal tubule epithelial cells into the tubule lumen by a transporter dependent on the binding of drug to albumin.26 Disruption of tubular secretion caused by competing substances (eg, non-steroidal anti-inflammatory drugs), hypoalbuminemia, metabolic alkalosis, or poor renal blood flow also could result in low uFureq despite apparent adequate PO dosages. None of our subjects had history of hypoalbuminemia or azotemia, but we did not specifically perform serum chemistries or blood gas analysis. Our results warrant future studies designed to specifically identify and treat these potential causes of low uNa and low uFureq. Another potential mechanism for low DR is impaired intrinsic nephron responsiveness. In this setting, bioavailability and tubular secretion are sufficient to result in high uFureq and blockade of the Na-2Cl-K cotransporter in the ascending loop of Henle. The resultant natriuresis reflects the nephron’s intrinsic responsiveness to cotransporter blockade. The pharmacodynamic effect of loop diuretics typically follows a sigmoidal curve with clinically used doses operating on the steep part of the curve and facilitating titration to a desired diuretic and natriuretic effect.27–29 This relationship can be altered by disease and resistance such that the dose response curve is flattened and shifted rightward, resulting in decreased natriuresis and DR for any given dose.28,30,31 We observed dogs with consistently low natriuresis in combination with relatively high uFureq, which suggests a flattened response curve and impaired nephron responsiveness. One cause of impaired nephron responsiveness is the braking effect associated with neurohormonal activation.32 This effect previously was demonstrated in healthy dogs receiving constant rate infusion of furosemide wherein the ratio of urinary sodium excretion to urine furosemide concentration steadily decreased over 5 h of treatment because of renin-angiotensin-aldosterone axis activation.17 The braking effect typically is considered a response to IV loop diuretics, but increased neurohormonal activity in chronic HF and PO diuretics can similarly decrease glomerular filtration rate, increase sodium reabsorption in distal nephron segments, stimulate non-osmotic vasopressin release, and disrupt tubuloglomerular feedback despite pharmacologic neurohormonal blockade.22 Chronic oral administration of loop diuretics is associated with distal convoluted tubular hypertrophy in animal models and also might occur in both humans and dogs.22,33,34 The result of such hypertrophy is increased sodium-potassium exchange that negates sodium blockade in the loop of Henle and decreases natriuresis while simultaneously promoting kaliuresis.22 In our study, uNa:K was significantly and positively associated with uFureq but uNa:K < 1 was observed in >50% of urine samples, which previously has been associated with low DR.3,17 Similar to the previous discussion, considering uNa and uFureq, specifically low uNa and high uFureq suggests specific hypotheses and treatment strategies for future studies. Diuretic responsiveness in veterinary species likely is associated with morbidity and mortality as it is in humans. The prognostic importance of low DR in humans with acute CHF is well described3,35,36 whereas less is known in humans with chronic CHF. In one study of humans with chronic CHF,16 the ratio of PO furosemide dose to spot uNa predicted 5-year mortality. Subjects with high ratios consistent with low DR had >3-fold risk of dying compared with those with higher responsiveness. In a second study of 1145 humans with chronic CHF, first morning urine samples with uNa <50 mmol/L were significantly associated with higher risk of worsening HF and hospitalization.20 In the same study, approximately 25% of subjects had uNa < 50 mmol/L, 50% had uNa <71 mmol/L, and 25% had uNa > 95 mmol/L, which is a distribution similar to what we observed in our study cohort. Risk of 1-year mortality in subjects in the lowest quartile was >2-fold higher than in subjects in the highest quartile. In a third study21 of 80 humans with chronic CHF, first morning spot uNa concentrations were measured once weekly for 30 consecutive weeks. Two different cohorts were studied, the first consisting of subjects with uNa consistently >88 mmol/L and the second consisting of subjects with uNa consistently <73 mmol/L. During follow-up, 21 subjects were admitted to the hospital for recurrence of acute CHF and had significantly lower uNa than subjects who remained free of congestion. Longitudinal changes in uNa were predictive. In the week immediately preceding hospitalization, uNa was observed to decrease to an average of 46 mmol/L, followed by a return to the individual’s baseline 1 week after successful decongestion and discharge from the hospital. In a fourth study,37 low 24-h urinary sodium excretion was associated with increased all-cause mortality. These data suggest that consistently low spot uNa in dogs with chronic CHF is likely an important clinical finding. Most of the aforementioned studies utilized first morning urine samples, suggesting that important information about DR and sodium avidity is not restricted to samples closely following PO diuretic administration. We detected low DR in dogs receiving relatively modest PO diuretic dosages. Existing treatment guidelines define diuretic resistance in dogs with chronic CHF based on the need for daily furosemide dosage ≥8 mg/kg/day.1 Implied in this definition is that dogs receiving lower dosages have adequate DR. Our study suggests that low DR is prevalent in dogs receiving dosages much lower than 8 mg/kg/day, including dosages as low as 2-4 mg/kg/day. The absence of association between dose and natriuresis observed in our study suggests that dose alone is an insufficient and unreliable criterion for DR. In our study, serial measurement of urine electrolyte concentrations and uFureq provided important information about the presence and potential causes of low DR. We explored a model involving uNa, uFureq, and PO diuretic dose to identify and examine potential causes of low DR in individual dogs. This approach generates a better understanding and testable hypotheses of low DR as well as its causes and diagnostic and treatment strategies. Our study had some important limitations. We observed evidence of low DR in dogs with mild to moderate CHF but study of dogs with more severe CHF and higher PO diuretic dosages would be a subject of interest. Furosemide and torsemide have important pharmacokinetic and pharmacodynamic differences, but we were unable to compare response between the 2 drugs. We collected samples from relatively few dogs, which lowers study power and ability to identify between-subject differences. Many conclusions from our study were based on the absence of significant associations between variables, but high P values and low estimates of effect from our analyses suggest a low likelihood of clinically important type II errors. Plasma loop diuretic concentrations were not measured, which prevented us from making specific conclusions about bioavailability or tubular secretion. Our study cohort included subjects with various forms of heart disease, and important pharmacologic or pharmacodynamic differences may exist depending on the underlying cause or whether the HF was left- or right-sided. Finally, most instances of low DR, especially those that are pathophysiological as opposed to pharmacologic, are likely multifactorial, making it unlikely that any single uNa or uFureq finding will be pathognomonic. We did not correct for multiple testing, and hypotheses generated by our observations should be considered as starting points for further investigation. In conclusion, uNa in in dogs with chronic CHF receiving loop diuretics PO was widely variable and not predicted by dose, timing of administration, or duration of treatment. Our cohort of dogs had consistently low uNa in keeping with definitions of low DR in humans and dogs. Concentration of urine furosemide equivalents was not significantly associated with diuretic dose or uNa, and this relationship was highly variable among individuals. Consideration of uNa, uFureq, and diuretic dose in individual dogs generated specific hypotheses regarding DR based on their relationship. Dogs with relatively high uNa and uFureq appeared to exhibit good responsiveness. Low uNa and low uFureq suggested mechanisms preventing PO diuretics from reaching the nephron lumen, such as poor bioavailability or impaired tubular secretion. Dogs with low uNa and high uFureq might be resistant because of impaired nephron function or neurohormonal activation. Quantification of DR using uNa sheds light on the variability of natriuresis and offers unique insights about potential causes of low DR and treatment strategies. Our results support redefining low DR or diuretic resistance in dogs based on measured uNa and other individual variables, rather than a universal definition based only on daily diuretic dosage.